| Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia JC Byrd, RR Furman, SE Coutre, IW Flinn, JA Burger, KA Blum, B Grant, ... New England Journal of Medicine 369 (1), 32-42, 2013 | 2765 | 2013 |
| Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib JA Woyach, RR Furman, TM Liu, HG Ozer, M Zapatka, AS Ruppert, L Xue, ... New England Journal of Medicine 370 (24), 2286-2294, 2014 | 1359 | 2014 |
| Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia JC Byrd, B Harrington, S O’Brien, JA Jones, A Schuh, S Devereux, ... New England Journal of Medicine 374 (4), 323-332, 2016 | 1016 | 2016 |
| Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 SEM Herman, AL Gordon, E Hertlein, A Ramanunni, X Zhang, ... Blood 117 (23), 6287-6296, 2011 | 1000 | 2011 |
| CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability BJ Lannutti, SA Meadows, SEM Herman, A Kashishian, B Steiner, ... Blood 117 (2), 591-594, 2011 | 875 | 2011 |
| Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib JC Byrd, RR Furman, SE Coutre, JA Burger, KA Blum, M Coleman, ... Blood, blood-2014-10-606038, 2015 | 849 | 2015 |
| Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes JA Dubovsky, KA Beckwith, G Natarajan, JA Woyach, S Jaglowski, ... Blood 122 (15), 2539-2549, 2013 | 828 | 2013 |
| Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival … SEM Herman, AL Gordon, AJ Wagner, NA Heerema, W Zhao, JM Flynn, ... Blood 116 (12), 2078-2088, 2010 | 732 | 2010 |
| Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug AG Ramsay, AJ Johnson, AM Lee, G Gorgün, R Le Dieu, W Blum, JC Byrd, ... The Journal of clinical investigation 118 (7), 2427-2437, 2008 | 725 | 2008 |
| Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial S O'Brien, RR Furman, SE Coutre, JP Sharman, JA Burger, KA Blum, ... The lancet oncology 15 (1), 48-58, 2014 | 714 | 2014 |
| Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia KJ Maddocks, AS Ruppert, G Lozanski, NA Heerema, W Zhao, L Abruzzo, ... JAMA Oncology 1 (1), 80-87, 2015 | 646 | 2015 |
| Genetic heterogeneity of diffuse large B-cell lymphoma J Zhang, V Grubor, CL Love, A Banerjee, KL Richards, PA Mieczkowski, ... Proceedings of the National Academy of Sciences 110 (4), 1398-1403, 2013 | 632 | 2013 |
| The B-cell receptor signaling pathway as a therapeutic target in CLL JA Woyach, AJ Johnson, JC Byrd Blood 120 (6), 1175-1184, 2012 | 536 | 2012 |
| BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia JA Woyach, AS Ruppert, D Guinn, A Lehman, JS Blachly, A Lozanski, ... Journal of Clinical Oncology 35 (13), 1437-1443, 2017 | 498 | 2017 |
| Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia JA Fraietta, KA Beckwith, PR Patel, M Ruella, Z Zheng, DM Barrett, ... Blood 127 (9), 1117-1127, 2016 | 497 | 2016 |
| Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia JC Byrd, TS Lin, JT Dalton, D Wu, MA Phelps, B Fischer, M Moran, ... Blood 109 (2), 399-404, 2006 | 460 | 2006 |
| Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience S O’Brien, RR Furman, S Coutre, IW Flinn, JA Burger, K Blum, J Sharman, ... Blood 131 (17), 1910-1919, 2018 | 434 | 2018 |
| Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia R Lapalombella, Q Sun, K Williams, L Tangeman, S Jha, Y Zhong, ... Blood 120 (23), 4621-4634, 2012 | 372 | 2012 |
| Ibrutinib treatment improves T cell number and function in CLL patients M Long, K Beckwith, P Do, BL Mundy, A Gordon, AM Lehman, ... The Journal of Clinical Investigation 127 (8), 3052-3064, 2017 | 355 | 2017 |
| Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy JA Woyach, K Smucker, LL Smith, A Lozanski, Y Zhong, AS Ruppert, ... Blood 123 (12), 1810-1817, 2014 | 347 | 2014 |
